Nov 13, 2023 8:30am EST LIXTE Biotechnology Provides Update on Clinical Progress and Expanding Collaborations
Oct 16, 2023 8:30am EDT LIXTE, Netherlands Cancer Institute, and Oncode Institute to Expand Collaboration
Oct 09, 2023 8:30am EDT LIXTE Biotechnology Holdings Announces the Passing of its Founder, John S. Kovach
Sep 20, 2023 8:30am EDT LIXTE Biotechnology Announces a Supported Collaborative Trial to Study LIXTE’s First-in-Class PP2A Inhibitor, LB-100, Plus GSK’s Immunotherapy, Dostarlimab, in Clear-Cell Ovarian Cancer
Jul 20, 2023 4:05pm EDT LIXTE Biotechnology Announces Closing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Jul 18, 2023 8:00am EDT LIXTE Biotechnology Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market under Nasdaq Rules
Jul 17, 2023 8:30am EDT Preclinical Results of LIXTE Biotechnology’s Collaboration with Netherlands Cancer Institute Reveal Novel Mechanism by which LIXTE’s Lead Clinical Compound LB-100 Enhances Effectiveness of Immunotherapy and Chemotherapy
Jun 23, 2023 8:30am EDT LIXTE Biotechnology Holdings, Inc. Regains Compliance with Nasdaq Continued Listing Requirements
Jun 07, 2023 8:30am EDT LIXTE Biotechnology and the Spanish Sarcoma Group Enroll First Patient in a Phase 1b/2 Randomized Trial of Doxorubicin +/- LIXTE’s Lead Anti-Cancer Compound, LB-100, in Advanced Soft Tissue Sarcomas
